Eyenovia (NASDAQ:EYEN) Given “Market Perform” Rating at William Blair

Eyenovia (NASDAQ:EYEN)‘s stock had its “market perform” rating reiterated by analysts at William Blair in a research note issued on Friday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Wednesday.

Eyenovia Trading Down 68.3 %

Eyenovia stock traded down $0.23 during trading hours on Friday, reaching $0.11. The stock had a trading volume of 38,368,520 shares, compared to its average volume of 1,382,547. The stock has a market cap of $6.91 million, a PE ratio of -0.14 and a beta of 1.75. The company has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $0.71. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. Eyenovia has a 52 week low of $0.09 and a 52 week high of $2.57.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the prior year, the firm posted ($0.18) EPS. Analysts forecast that Eyenovia will post -0.56 EPS for the current fiscal year.

Insider Activity

In other news, CEO Michael M. Rowe acquired 50,000 shares of the stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at $47,268.39. This represents a 151.85 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Armistice Capital LLC bought a new stake in Eyenovia during the second quarter worth about $3,601,000. Vanguard Group Inc. increased its position in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Eyenovia by 1,444.4% in the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after acquiring an additional 205,390 shares in the last quarter. SkyView Investment Advisors LLC purchased a new stake in shares of Eyenovia in the second quarter worth $87,000. Finally, Financial Management Network Inc. bought a new position in shares of Eyenovia during the third quarter valued at $39,000. 25.84% of the stock is currently owned by institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.